Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 147
- Uncategorized
Grow Group plant Börsengang in den nächsten 12 Monaten” nach deutscher Expansion
Die GROW Group teilte BusinessCann im Jahr 2020 mit, dass sie 6 Millionen Pfund Kapital aufnimmt, um ihre Expansion in ganz Europa zu finanzieren, wobei sie den deutschen Markt für medizinischen Cannabis ins Visier nimmt.
- Medical
The Medical Cannabis Industry Was ‘Started By Patients’ And They Play An ‘Important Role’ In Pushing It Forward
ACCORDING to the most recent figures from Prohibition Partners’ European Cannabis Report, the number of privately prescribed, unlicensed medical cannabis items dispensed in the UK last year jumped 425% to 23,466.
- Pharmaceutical
EU Cannabis Stocks Review: Love Hemp & Yooma Wellness Both See Their Shares Suspended
It has been another dramatic week on the global markets, with the Pound Sterling falling to a 2022-low and the NASDAQ registering its biggest one-day decline since June 2020 on continued fears of runaway inflation.
- CBD Market
‘Muddled’ Handling Of CBD Public List Has Impacted Businesses & Wider Industry
THE Food Standards Agency (FSA) last week added a further 2446 products to its public list of CBD items which are allowed to remain on sale in the UK.
- News
CBD Parliamentary Group Calls For Creation Of New Industry Body To Have ‘Real Impact’ On Guiding Future Regulation
LAST week the All Party Parliamentary Group (APPG) for CBD Products called on the Government to establish a single ‘genuinely industry-representative’ body to guide the future framework of CBD in the UK.
- Medical
Ananda Developments Makes 3 New Heavyweight Hires As It Continues ‘Best, Not First’ Strategy
ANANDA Developments has announced a number of heavyweight hires including a new COO, Head of Cultivation and Head of Plant Science, sending its stock price jumping nearly 30%.
- Markets & Stocks
EU Cannabis Stocks Review: Akanda’s Streak Comes To Abrupt End & Chill Brands New CEO Has His Work Cut Out To Recover Losses
This week was another difficult week for cannabis stocks across global markets, with a number of external factors seeing both the NASDAQ and LSE succumb to pressures, bringing many cannabis stocks down in tandem.
- Pharmaceutical
Jazz Pharma Backs Crackdown On UK CBD Industry Amid Inquiry Into UK Drug Law
YESTERDAY morning the Home Affairs Committee held the opening session of its new inquiry into drugs, seeking to examine the impact and efficacy of the ‘current legislative framework’.
- News
MGC Pharmaceuticals Says New Deal Will Propel It ‘Into The World Of True Pharma’ As It Appoints New CFO
MGC Pharmaceuticals has announced the appointment of a new CFO in the latest of a flurry of updates from the company, which says it is on the precipice of breaking into the world of ‘true pharma’.
- CBD Market
Recommended THC Limits Would Mean ‘No Jobs, Industry or Farming’ In The UK Says CBD APPG Secretariat Tenacious Labs
TENACIOUS Labs, which launched into the cannabis market last year with a flurry of acquisitions across the US and UK, was appointed as secretariat of the CBD (Cannabidiol) Products All Party Parliamentary Group just months later.
- Medical
New Pilot Could See Patients On The Isle Of Man Gain Access To Medical Cannabis For The First Time
THE Isle of Man’s 83,000 inhabitants could soon gain access to medical cannabis for the first time as the Department of Health & Social Care (DHSC) prepares to launch a new pilot scheme.
- Markets & Stocks
European Cannabis Stocks Review: FSA Makes ‘Final Call’ For Evidence As Cellular Goods’ Stock Recovers From Confusion Over Its Products’ Inclusion
THE fallout from the publication of the FSA’s Public List is continuing to be felt on the stock markets this week, with the regulator issuing a ‘final call’ for evidence after a number of CBD companies came forward with ‘new evidence linking large numbers of individual products to applications.’












